|Biotech partner:||Swedish Orphan Biovitrum (Sweden) Biomodels (USA)|
|Type of agreement:||* R&D
|Compound:||assay for mucositis risk in cancer treatment|
|Disease area:||mucositis risk in cancer treatment|
|Nature of the agreement:||Swedish Orphan Biovitrum and Biomodels have announced a research agreement, under which Biomodels will explore the possibility of developing a clinically applicable screening platform that will define mucositis risk among patients undergoing conditioning regimens for hematopoietic stem cell transplants (HSCT).|
|Financial terms of the agreement:||Swedish Orphan Biovitrum will provide funding for the project.